ArticleFrontiers in oncology2025
DeepGlioSeg: advanced glioma MRI data segmentation with integrated local-global representation architecture.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A functionally guided fusion Vision Transformer for predicting IDH status in gliomas: a multicenter study with external validation and incomplete multimodal evaluation.Radiologie (Heidelberg, Germany) · 2026Article
- Validation of open-source deep learning segmentation tools for automated glioma volumetry: a narrative review of Dice scores, workflow efficiency, and clinical RANO 2.0 implementation.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Glioma segmentation is vital for diagnostic decision-making, monitoring disease progression, and surgical planning. However, this task is hindered by substantial heterogeneity within gliomas and imbalanced region distributions, posing challenges to existing segmentation methods. Methods: To address these challenges, we propose the DeepGlioSeg network, a U-shaped architecture with skip connections for continuous contextual feature integration. The model includes two primary components. First, a CTPC (CNN-Transformer Parallel Combination) module leverages parallel branches of CNN and Transformer networks to fuse local and global features of glioma images, enhancing feature representation. Second, the model computes a region-based probability by comparing the number of pixels in tumor and background regions and assigns greater weight to regions with lower probabilities, thereby focusing on the tumor segment. Test-time augmentation (TTA) and volume-constrained (VC) post-processing are subsequently applied to refine the final segmentation outputs. Results: Extensive experiments were conducted on three publicly available glioma MRI datasets and one privately owned clinical dataset. The quantitative and qualitative findings consistently show that DeepGlioSeg achieves superior segmentation performance over other state-of-the-art methods. Discussion: By integrating CNN- and Transformer-based features in parallel and adaptively emphasizing underrepresented tumor regions, DeepGlioSeg effectively addresses the challenges associated with glioma heterogeneity and imbalanced region distributions. The final pipeline, augmented with TTA and VC post-processing, demonstrates robust segmentation capabilities. The source code for this work is publicly available at https://github.com/smallboy-code/Brain-tumor-segmentation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.